Lone Star Bio
Filter News
Found 18,184 articles
-
Autonomix Appoints Jennifer Cook as Chief Business Officer
3/19/2024
Autonomix Medical, Inc. today announced the appointment of Jennifer Cook as its Chief Business Officer.
-
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
3/19/2024
Genprex, Inc. today announced that it has entered into definitive agreements for the sale and issuance of 1,542,112 shares of common stock.
-
Lucas Vitale Joins Orthofix as Chief People and Business Operations Officer
3/18/2024
Orthofix Medical Inc., a leading global spine and orthopedics company, announced that Lucas Vitale has joined the company in the newly created role of Chief People and Business Operations Officer.
-
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
3/18/2024
Natera, Inc. announced a collaboration with the Fédération Francophone de Cancérologie Digestive and CHU Dijon Bourgogne on the CIRCULATE-PRODIGE-70 study, a randomized, multicenter, prospective phase III clinical trial in France investigating molecular residual disease -guided adjuvant treatment in stage II colorectal cancer patients.
-
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
3/18/2024
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its 2023 results and provided a business update.
-
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
3/18/2024
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the fourth quarter and fiscal year ended December 31, 2023.
-
Monogram Orthopaedics Reports Full Year 2023 Financial Results
3/15/2024
Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, has reported its financial and operational results for the fourth quarter and full year ended December 31, 2023.
-
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
3/15/2024
Castle Biosciences, Inc. announced new data highlighting the value of its IDgenetix pharmacogenomic test in guiding medication recommendations for patients with mental health conditions who are 65 and older.
-
Dr. Ameer Hassan Establishes Distinctive Scholarship to Foster Excellence in Medical Education
3/15/2024
Dr. Ameer Hassan, a distinguished figure in the realm of neurology and neuroendovascular medicine, proudly announces the establishment of the Dr. Ameer Hassan Scholarship for Medical Students.
-
Nutex Health Announces Preliminary 2023 Headline Financials and Provides Update on the Timing of Its 10-K Filing
3/15/2024
Nutex Health Inc. announced preliminary FY 2023 headline financials and provides an update on the anticipated timing for the filing of its 10-K for the year ended December 31, 2023.
-
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
3/15/2024
Lantern Pharma today announced the dosing of the first two patients in the Phase 1 clinical trial evaluating Lantern’s investigational new drug LP-284 in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL), including mantle cell lymphoma (MCL) and double hit lymphoma (DHL) and other high-grade B-cell lymphomas (HGBL) as well as other select solid tumors and sarcomas.
-
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
3/14/2024
Natera, Inc., a global leader in cell-free DNA testing, commented on the 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, which was recently published by the Kidney Disease Improving Global Outcomes organization, a leading medical society in nephrology.
-
Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
3/14/2024
Autonomix Medical, Inc. today announced the safe completion of the first three patient procedures for its proof-of-concept (PoC) human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain.
-
Form Bio Helps Life Sciences Professionals Transform Omics Data Into Breakthrough Insights Through Google Cloud
3/14/2024
Form Bio , the breakthrough computational life sciences solutions provider, today announced the availability of Google Cloud's innovative AI-based models for healthcare and life sciences research as point-and-click workflows via Form Bio's bioinformatics platform.
-
TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024
3/14/2024
TFF Pharmaceuticals, Inc. announced that Harlan Weisman, M.D., Chief Executive Officer of TFF Pharmaceuticals will be presenting a corporate overview at the 36th Annual Roth Conference being held March 17-19, 2024 in Dana Point, California.
-
Arcadia Biosciences (RKDA) Announces Date of Fourth Quarter 2023 Financial Results and Business Highlights Conference Call
3/14/2024
Arcadia Biosciences, Inc. today announced that it will release its financial and business results for the fourth quarter and full year of 2023 after market close on March 28, 2024.
-
Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen's Off-the-shelf CAR-T Cellular Therapies
3/14/2024
Cellipont Bioservices and Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced the signing of an agreement for the manufacturing of their CAR-T cell therapies.
-
HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
3/14/2024
Heart Test Laboratories, Inc.d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company") today reported financial results for the third quarter fiscal 2024 ended January 31, 2024 and provided a business update.
-
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
3/14/2024
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company) today announced that it will report its financial results for the full-year ended December 31, 2023, provide corporate and clinical updates and host a corporate update conference call on Tuesday, March 19, 2024, at 4:30 PM Eastern Time.
-
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
3/13/2024
Nexalin Technology, Inc. today announced it was selected and provided a poster presentation at the “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment” on March 12, 2024, which was held at the Walter E. Washington Convention Center in Washington, D.C.